University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 4 of 12
Behavioral Activation, Nutrition, and Activity Intervention
NCT06239961
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
NCT05521880
Effect of Estradiol Topical Products
NCT05645393
Medical Effects of Proximal (In-person) Intercessory (PIP) and Virtual Intercessory Prayer (VIP) on Pain and Anxiety
NCT07565142
Estrogen Hormone Products
NCT05645406
Dietary Nitrate Functional Gum Effect on Gingivitis and Heart Health
NCT06029283
Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors
NCT05499663
Blended Reality Immersion for Geriatric Head Trauma: The BRIGHT Study
NCT06074328
Massage Therapy in Premature Neonates
NCT06163586
Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
NCT05908526
Protective Arm Balance Responses
NCT06388434
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
NCT05854485
Diagnostic Stewardship for Ventilator Associated Pneumonia
NCT05989269
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
NCT05582707
Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis
NCT05406726
SBIRT Intervention for Gambling Behaviors
NCT03287583
DMID 21-0041; Influenza CVD 59000
NCT05666245
Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21
NCT05452902
TMS Related Biomarker Assessments
NCT05660018
Neural Mechanisms of Motor Recovery With Technology Assisted Training
NCT05560867
Social Work Assistance and Stipends for Housing (SASH)
NCT05803603
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
NCT04634513
COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2
NCT05196932
Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease
NCT05525546
Worksite Wellness Within Long-term Care Facilities
NCT04166643
Palliative Care for Persons With ADRD and CI in SNF
NCT05308004
Luteolin for the Treatment of People With Schizophrenia
NCT05204407
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
NCT05142228
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
NCT05162027
Clinical Decision Support Tool for Vancomycin Dosing in Children
NCT04911270
Ketamine for OUD and Comorbid Depression (OUDCD)
NCT05051449
The Utility of the Validated Intraoperative Bleeding Scale in Spine Surgery
NCT05258487
Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
NCT05268302
Tendon Transfer Rotator Cuff Tear
NCT04588506
Risk Factors, Costs, and Impacts of ED Boarding
NCT07532564
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04896658
Exercise Plus Duloxetine for Knee Osteoarthritis
NCT04111627
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
NCT04800471
Implementation of a Telehealth Palliative Care Model for Persons With Dementia
NCT05001620
Cigarette Smoking in Smokers With and Without Schizophrenia
NCT04001114
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
NCT04827745
Impact of Counseling and Education on Opioid Consumption After ACL Reconstruction
NCT04885231
Heterotopic Ossification Prophylaxis
NCT04867278
Treat COVID-19 Patients With Regadenoson
NCT04606069
Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
NCT04332211
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
NCT04640571
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
NCT04666649
Impact of a Yoga Intervention on Pain and Multiomics in Participants With IBS
NCT04315714
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT04527900
Pilot Testing the Check Up
NCT04624074
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets.Report a data error.